banner
Bivona Lab »  Meet the Team »  Postdoctoral Fellows »  Collin Blakely, M.D., Ph.D.

Collin Blakely, M.D., Ph.D.

Clinical Instructor
Division of Hematology/Oncology
Department of Medicine

Contact Information

600 16th Street,Genentech Hall
Room N216
San Francisco, CA 94158
Collin.Blakely@ucsf.edu
  • University of Washington, B.S. 1997

  • University of Pennsylvania, M.D., Ph.D. 2007
  • Hospital of the University of Pennsylvania, Internship in Internal Medicine, 2007-2008

  • Hospital of the University of Pennsylvania, Residency in Internal Medicine, 2008-2009
  • UCSF, Fellowship in Medical Oncology, 2009-2011
  • Postdoctoral Fellow - UCSF, Lisa Coussens Laboratory, 2010-2012

  • Postdoctoral Fellow - UCSF, Trever Bivona Laboratory, 2012-2014
  • Non-small cell lung cancer
  • Small cell lung cancer
  • ALK-rearranged lung cancer
  • EGFR-mutant lung cancer
  • Mechanisms of resistance to targeted therapies
  • ROS1-rearranged lung cancer

Collin is a medical oncologist specializing in the treatment of lung cancer. He received his Bachelor of Science degree in Molecular and Cellular Biology from the University of Washington and attended the Perelman School of Medicine at the University of Pennsylvania in the Medical Scientist Training Program. He completed his Internal Medicine residency at the Hospital of the University of Pennsylvania and trained as a clinical fellow in Medical Oncology at UCSF. His research focuses on understanding the cellular and molecular mechanisms underlying lung cancer resistance to EGFR-targeted therapies. His goal is to translate laboratory-based findings into new treatments for lung cancer patients.

The primary focus of my research is to translate laboratory-based findings into novel investigator sponsored trials that aim to assess the safety and efficacy of rationally designed targeted therapies for lung cancer patients.

My goals are to: 1) define how TKI resistance pathways evolve at the tumor genome, transcriptome and molecular signaling levels within lung cancers and to translate these findings into novel prognostic and predictive biomarkers that may predict TKI resistance before it occurs; 2) develop investigator sponsored clinical trials to test rational companion therapies that can prevent, delay, or overcome TKI resistance, 3) develop investigator sponsored clinical trials to target recently identified oncogenic pathways, outside of EGFR and ALK, that drive NSCLC; and 4) establish a cohort of patient-derived xenograft (PDX) mice to foster research that aims to further understand the molecular mechanisms of response and resistance to TKI therapies in lung cancer

  • Uniting Against Lung Cancer, 2014-2016, AACR 2014 - 2016
Most recent publications from a total of 11
  1. Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, Jablons DM, Johnson JR, Bandyopadhyay S, Krogan NJ, Bivona TG. NF-?B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Rep. 2015 Mar 31. View in PubMed
  2. Blakely CM, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012 Oct; 2(10):872-5. View in PubMed
  3. Blakely C, Jahan T. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2011 Oct; 11(10):1607-18. View in PubMed
  4. Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Res. 2006 Jun 15; 66(12):6421-31. View in PubMed
  5. Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA. Developmental stage determines the effects of MYC in the mammary epithelium. Development. 2005 Mar; 132(5):1147-60. View in PubMed
  6. Gale M, Blakely CM, Darveau A, Romano PR, Korth MJ, Katze MG. P52rIPK regulates the molecular cochaperone P58IPK to mediate control of the RNA-dependent protein kinase in response to cytoplasmic stress. Biochemistry. 2002 Oct 1; 41(39):11878-87. View in PubMed
  7. Tan SL, Tareen SU, Melville MW, Blakely CM, Katze MG. The direct binding of the catalytic subunit of protein phosphatase 1 to the PKR protein kinase is necessary but not sufficient for inactivation and disruption of enzyme dimer formation. J Biol Chem. 2002 Sep 27; 277(39):36109-17. View in PubMed
  8. Katze MG, Kwieciszewski B, Goodlett DR, Blakely CM, Neddermann P, Tan SL, Aebersold R. Ser(2194) is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Virology. 2000 Dec 20; 278(2):501-13. View in PubMed
  9. Ladiges W, Morton J, Blakely C, Gale M. Tissue specific expression of PKR protein kinase in aging B6D2F1 mice. Mech Ageing Dev. 2000 Mar 13; 114(2):123-32. View in PubMed
  10. Gale M, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM, Korth MJ, Polyak SJ, Gretch DR, Katze MG. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol. 1998 Sep; 18(9):5208-18. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Collin Blakely, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X